We have 4 of 104 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
TP53 and FOXA1 mutations, observed in primary and metastatic castration-resistant prostate cancer, were associated with aggressive disease phenotypes and potential therapeutic resistance, and these findings highlight TP53 and FOXA1 as promising biomarkers and potential therapeutic targets in prostate cancer.
This review traces how heavy metals including Pb, Cd, As, Hg, Cr and Ni along with pesticide residues enter medicinal plants, disrupt their physiology, impair secondary metabolite production and ultimately reach human consumers.
Unraveling the intricate mechanisms of EMT activation in cancer will contribute to the advancement of personalized medicine and the design of more effective treatments against metastatic disease and pave the way for advancements in personalized medicine and improved treatment strategies for patients affected by EMT-related conditions.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
